Operational value
Faster evidence reconciliation
IBDCP architecture
Trusted pharmaceutical and life-sciences data
IBDCP can connect batch, quality, release and logistics evidence across independent systems while preserving source authority and custody. It supports a verifiable data path; it does not replace regulated quality systems or validation duties.
The business problem
Manufacturing, laboratory, quality and logistics records frequently cross organisational and technical boundaries before a product can be released or investigated.
How IBDCP addresses it
A governed trust layer links events from approved systems and parties, preserving evidence for authorised decisions without centralising all regulated data.
Identify the regulated decision point
Approve source systems and authorities
Bind batch events to evidence
Verify release or exception decisions
Decision relevance
Trust value
Clearer cross-party accountability
Architecture value
A reusable path for provenance and investigation
Security and governance boundary
Regulated organisations retain responsibility for validation, data integrity, qualified systems and human release authority.
Implementation evidence
The same custody and provenance patterns used in eKarton and supply-chain cases can be adapted to validated pharmaceutical workflows after domain assessment.
Related evidence and capabilities
Next decision
Evaluate one bounded business process.
Start with the workflow where fragmented authority, custody or provenance is already creating cost, delay or risk.
Assess the business case